免疫检查点抑制剂的心血管并发症
本文综述免疫检查点抑制剂(ICI)对心血管系统的影响,涵盖其背景、流行病学、潜在机制及心血管生物学启示,并提出诊断与治疗思路。文章指出ICI相关心血管事件已从暴发性心肌炎扩展至无心肌炎的心功能障碍、心律失常、静脉血栓栓塞、动脉粥样硬化加速及动脉粥样硬化相关心血管事件,且事件可发生于治疗开始后数周内及数月至数年之后。
要点
- ICI可致暴发性心肌炎,并可出现无心肌炎的心功能障碍与心律失常。
- ICI相关心血管事件还包括静脉血栓栓塞、动脉粥样硬化加速及相关事件。
- 心血管事件可见于治疗开始后数周内,也可见于数月至数年之后。
核心结论
- ICI治疗与多种心血管事件增加相关,需从识别事件转向理解机制、识别高危人群并探索干预措施。
研究设计与样本
- 本文为综述,聚焦免疫检查点抑制剂的心血管效应,介绍其背景、流行病学、潜在机制及诊断治疗思路。
主要发现
- 初始观察发现ICI治疗可导致暴发性心肌炎。
- 近期报告将ICI的心血管影响扩展至无心肌炎的心功能障碍、心律失常、静脉血栓栓塞、动脉粥样硬化加速及动脉粥样硬化相关心血管事件。
- ICI与上述心血管事件增加的关联不限于治疗开始后最初数周内,也包括治疗数月至数年后发生的事件。
- 后者对接受辅助或新辅助治疗者尤其相关。
临床怎么用
- 对接受ICI治疗者应关注心肌炎以外的心血管事件,包括心功能障碍、心律失常、静脉血栓栓塞及动脉粥样硬化相关事件。
- 对接受辅助或新辅助ICI治疗者,心血管风险的随访评估需延伸至治疗结束后数月至数年。
局限性
- 文中指出对ICI心血管效应的认识仍需提高,机制、高危人群识别及干预措施尚待明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the last decade or so, there has been a paradigm shift in the oncologic care of patients with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic chemotherapy and towards personalized cancer treatments, using both targeted therapy and immunotherapy. This shift has contributed to the remarkable and sustained increase in the number of cancer survivors and the longevity of patients with a cancer diagnosis. This review will focus on the cardiovascular effects of immune checkpoint inhibitors and will present a background on immune checkpoint inhibition for cancer, the epidemiology, potential mechanisms, the potential insights into cardiovascular biology, and a diagnostic and therapeutic approach to potential cases. Our understanding of the cardiovascular effects of immune checkpoint inhibitors needs to improve. However, the evolution necessarily needs to be rapid. Initial observations noted that immune checkpoint inhibitor therapy can lead to a fulminant myocarditis. Recent reports have expanded the effect of immune checkpoint inhibitor therapy on the cardiovascular system to include an increase in cardiac dysfunction without myocarditis, arrhythmias, venous thromboembolic disease, accelerated atherosclerosis, and atherosclerosis-related cardiovascular events. The association between immune checkpoint inhibitor therapy and an increase in these cardiovascular events is not only limited to events occurring within the first few weeks after starting therapy but can also include events that occur months to years after therapy. The latter observation is especially of relevance in those treated with adjuvant or neoadjuvant therapy. There needs to be a shift from recognition of an increase in cardiovascular events to currently approved immune checkpoint inhibitor therapies to understanding the mechanisms that lead to adverse cardiovascular effects, understanding who is at risk, and understanding what we can do about it.
引用
- Thuny F, Naidoo J, Neilan TG, et al. Cardiovascular complications of immune checkpoint inhibitors for cancer. Eur Heart J. 2022. PMID: 36040835. doi:10.1093/eurheartj/ehac456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。